Ingelfinger rule

Last updated

The Ingelfinger rule is an eponymous rule named after Franz J. Ingelfinger, The New England Journal of Medicine (NEJM) editor-in-chief who enunciated it in 1969. Editorials in most journals were published anonymously that time, so the paper was published without an author's name. [1] This rule - basically meant for scientific publishing, was originally meant only for NEJM. The rule was, that NEJM would not publish findings that had been published elsewhere, in other media or in other journals. The rule was subsequently adopted by several other scientific journals, and has shaped scientific publishing ever since. [2] Historically it has also helped to ensure that the journal's content is fresh and does not duplicate content previously reported elsewhere, [3] and seeks to protect the scientific embargo system. [4]

Contents

An earlier version of the policy had been expressed in 1960 by Samuel Goudsmit, editor of the Physical Review Letters , but did not become as well known. [5]

The Ingelfinger rule has been seen as having the aim of preventing authors from performing duplicate publications which would unduly inflate their publication record. [6] On the other hand, it has also been stated that the real reason for the Ingelfinger rule is to protect the journals' revenue stream, and with the increase in popularity of preprint servers [7] such as arXiv, bioRxiv, and HAL many journals have loosened their requirements concerning the Ingelfinger rule. [8] In a defense of the policy, the journal said in an editorial that the practice discouraged scientists from talking to the media before their work was peer reviewed. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Scientific misconduct</span> Violation of codes of scholarly conduct and ethical behavior in scientific research

Scientific misconduct is the violation of the standard codes of scholarly conduct and ethical behavior in the publication of professional scientific research. It is violation of scientific integrity: violation of the scientific method and of research ethics in science, including in the design, conduct, and reporting of research.

<span class="mw-page-title-main">Preprint</span> Academic paper prior to journal publication

In academic publishing, a preprint is a version of a scholarly or scientific paper that precedes formal peer review and publication in a peer-reviewed scholarly or scientific journal. The preprint may be available, often as a non-typeset version available free, before or after a paper is published in a journal.

<span class="mw-page-title-main">Open access</span> Research publications distributed freely online

Open access (OA) is a set of principles and a range of practices through which nominally copyrightable publications are delivered to readers free of access charges or other barriers. With open access strictly defined, or libre open access, barriers to copying or reuse are also reduced or removed by applying an open license for copyright, which regulates post-publication uses of the work.

<i>The Lancet</i> Peer-reviewed general medical journal

The Lancet is a weekly peer-reviewed general medical journal and one of the oldest of its kind. It is also one of the world's highest-impact academic journals. It was founded in England in 1823.

The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. Founded in 1812, the journal is among the most prestigious peer-reviewed medical journals. Its 2023 impact factor was 96.2, ranking it 2nd out of 168 journals in the category "Medicine, General & Internal".

Science by press conference or science by press release is the practice by which scientists put an unusual focus on publicizing results of research in the news media via press conferences or press releases. The term is usually used disparagingly, to suggest that the seekers of publicity are promoting claims of questionable scientific merit, using the media for attention as they are unlikely to win the approval of the scientific community.

<span class="mw-page-title-main">News embargo</span> Tactic for delaying publication by the press of a news item

In journalism and public relations, a news embargo or press embargo is a request or requirement by a source that the information or news provided by that source not be published until a certain date or certain conditions have been met. They are often used by businesses making a product announcement, by medical journals, and by government officials announcing policy initiatives; the media is given advance knowledge of details being held secret so that reports can be prepared to coincide with the announcement date and yet still meet press time.

<span class="mw-page-title-main">Arnold S. Relman</span> American internist, professor and journal editor (1923–2014)

Arnold Seymour Relman — known as Bud Relman to intimates — was an American internist and professor of medicine and social medicine. He was editor of The New England Journal of Medicine (NEJM) from 1977 to 1991, where he instituted two important policies: one asking the popular press not to report on articles before publication and another requiring authors to disclose conflicts of interest. He wrote extensively on medical publishing and reform of the U.S. health care system, advocating non-profit delivery of single-payer health care. Relman ended his career as professor emeritus at Harvard Medical School in Boston, Massachusetts.

Nature Precedings was an open access electronic preprint repository of scholarly work in the fields of biomedical sciences, chemistry, and earth sciences. It ceased accepting new submissions as of April 3, 2012.

Open peer review is the various possible modifications of the traditional scholarly peer review process. The three most common modifications to which the term is applied are:

  1. Open identities: Authors and reviewers are aware of each other's identity.
  2. Open reports: Review reports are published alongside the relevant article.
  3. Open participation: The wider community are able to contribute to the review process.

Ravgen Inc. is a privately owned biotech company founded in 2000 by Chairman and C.E.O. Dr. Ravinder Dhallan. Ravgen Inc. performs research in the prenatal diagnostic field and has developed non-invasive prenatal diagnosis testing for Down Syndrome.

Franz Joseph Ingelfinger was a German-American physician, researcher and journal editor. He served as Chief of Gastroenterology at Evans Memorial Department of Clinical Research, part of Boston University School of Medicine. He also served as Editor of the New England Journal of Medicine (NEJM) from 1967 to 1976. His work was influential in the field of science journalism.

Mandeep R. Mehra is The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and a professor of medicine at Harvard Medical School. He is the medical director of the Brigham Heart and Vascular Center in Boston, Massachusetts, and specializes in advanced heart failure, mechanical circulatory support and cardiac transplantation.

Annarosa Leri is a medical doctor and former associate professor at Harvard University. Along with former professor Piero Anversa, Leri was engaged in biomedical research at Brigham and Women’s Hospital in Boston, an affiliate of Harvard Medical School. Since at least 2003 Anversa and Leri had investigated the ability of the heart to regenerate damaged cells using cardiac stem cells.

bioRxiv Preprint service

bioRxiv is an open access preprint repository for the biological sciences co-founded by John Inglis and Richard Sever in November 2013. It is hosted by the Cold Spring Harbor Laboratory (CSHL).

<span class="mw-page-title-main">Nicholas White (physician)</span> British medical doctor and researcher

Sir Nicholas John White is a British medical doctor and researcher, specializing in tropical medicine in developing countries. He is known for his work on tropical diseases, especially malaria using artemisinin-based combination therapy.

Surgisphere is an American healthcare analytics company established in 2008 by Sapan Desai. Originally a textbook marketing company, it came under scrutiny in May 2020 after it provided large datasets of COVID-19 patients that were subsequently found to be unreliable. The questionable data were used in studies published in The Lancet and The New England Journal of Medicine in May 2020, suggesting that COVID-19 patients on hydroxychloroquine had a "significantly higher risk of death". In light of these studies, the World Health Organization decided to temporarily halt global trials of the drug hydroxychloroquine to treat COVID-19. After the studies were retracted, the WHO trials were resumed and then discontinued shortly after.

<span class="mw-page-title-main">Peer Community in</span> Scientific organization

Peer Community in (PCI) is a non-profit scientific organization that offers an editorial process of open science by creating specific communities of researchers reviewing and recommending preprints in their field. Since 2021, a new journal, Peer Community Journal, publishes recommended preprints.

Joseph Garland (1893–1973) was an American pediatrician and editor of The New England Journal of Medicine.

References

  1. ↑ "Definition of "sole contribution"". N Engl J Med. 281 (12): 676–677. September 1969. doi:10.1056/NEJM196909182811208. PMID   5807917.
  2. ↑ Marshall, E (1998). "Franz Ingelfinger's Legacy Shaped Biology Publishing". Science . 282 (5390): 861–3, 865–7. doi: 10.1126/science.282.5390.861 . PMID   9841429.
  3. ↑ "Ingelfinger rule definition". Medicine.net. 13 June 2000. Archived from the original on 2014-07-11. Retrieved 2011-08-20.
  4. ↑ Schachtman, NA (20 June 2014). "Selective Leaking — Breaking Ingelfinger's Rule". Schachtman Law Blog. Retrieved 2015-05-23.
  5. ↑ Lewenstein, BV (1988). "It's Not Really the Relman Rule". ScienceWriters. 36 (2): 17–18.
  6. ↑ Lariviere, V; Gingras, Y (2009). "On the prevalence and scientific impact of duplicate publications in different scientific fields (1980-2007)". arXiv: 0906.4019 [physics.soc-ph].
  7. ↑ Heidary, Fatemeh; Gharebaghi, Reza (2021-05-31). "COVID-19 impact on research and publication ethics". Medical Hypothesis, Discovery & Innovation in Ophthalmology. 10 (1): 1–4. doi: 10.51329/mehdiophthal1414 . ISSN   2322-3219. PMC   10460218 . PMID   37641621. S2CID   236407601.
  8. ↑ Borgman, CL (2007). Scholarship in the digital age: information, infrastructure, and the Internet. MIT Press. p. 99. ISBN   978-0-262-02619-2.
  9. ↑ Angell, M; Kassirer, J (1991). "The Ingelfinger Rule Revisited". The New England Journal of Medicine . 325 (19): 1371–1373. doi: 10.1056/NEJM199111073251910 . PMID   1669838.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.